Compare Marvell Technology Inc (MRVL) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Marvell Technology (MRVL) trades at $245.28, down 7.74% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $327.86 implying significant upside. The company reported three consecutive quarterly EPS beats, with Q3 2026 expected at $1.1, and projects robust revenue growth, particularly in its custom AI chip business, which is forecast to more than double by fiscal 2028. Despite a net loss in 2025, improving operating cash flow and a strong gross margin of 52.21% highlight underlying operational strength.

The outlook for MRVL is positive, driven by AI-driven demand in data centers and custom silicon deals with hyperscalers like Google, though high valuation multiples (P/E of 88.98) and execution risks in scaling custom chip production pose challenges. Investor sentiment remains bullish, with 83.79% of analysts rating the stock a buy, but volatility near all-time highs and competitive pressures warrant caution.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.